search
Back to results

Added Value of Automated Electrical Source Localization (EPILOG PreOp®) to Presurgical Evaluation of Refractory Epilepsy (EPILOG)

Primary Purpose

Epilepsies, Partial

Status
Unknown status
Phase
Not Applicable
Locations
Belgium
Study Type
Interventional
Intervention
electrical source imaging
Sponsored by
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Epilepsies, Partial focused on measuring epilepsy, drug resistant epilepsy, electrical source imaging, surgery

Eligibility Criteria

undefined - 65 Years (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • drug resistant epilepsy under presurgical evaluation
  • non lesional 3Tesla MRI scan
  • epileptic seizure(s) recorded during video-EEG monitoring

Exclusion Criteria:

  • patient does not agree for follow-up during 6 months
  • patient has an obvious causal lesion on MRI scan

Sites / Locations

  • Saint-Luc University HospitalRecruiting
  • Centre Hospitalier William LennoxRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Epilog Preop

Arm Description

patients receive Epilog preop analysis

Outcomes

Primary Outcome Measures

Quantification of Epilog+ driven changes of management plan
Descriptive analysis of population with results from Epilog Preop analysis that changed initial clinical decision (total number of patients, type management plan modification)

Secondary Outcome Measures

Sensitivity and specificity of Epilog+ compared to resection zone
Are Epilog+ results in the same location as the resection zone?
Sensitivity and specificity of Epilog+ compared to pathology
Are Epilog+ results identifying abnormal cortex?
Sensitivity and specificity of Epilog+ compared to seizure outcome
What proportion of patients are seizure free if Epilog+ results are resected; what proportion of patients are not seizure free if Epilog + results are not resected?

Full Information

First Posted
March 6, 2019
Last Updated
March 18, 2019
Sponsor
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
search

1. Study Identification

Unique Protocol Identification Number
NCT03882151
Brief Title
Added Value of Automated Electrical Source Localization (EPILOG PreOp®) to Presurgical Evaluation of Refractory Epilepsy
Acronym
EPILOG
Official Title
What is the Added Clinical Value of an Automated EEG Analysis Program With Electrical Source Localization (EPILOG PreOp®) as Part of the Pre-surgical Assessment of Non-lesional Refractory Epilepsy?
Study Type
Interventional

2. Study Status

Record Verification Date
March 2019
Overall Recruitment Status
Unknown status
Study Start Date
January 15, 2019 (Actual)
Primary Completion Date
June 1, 2020 (Anticipated)
Study Completion Date
December 31, 2020 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Cliniques universitaires Saint-Luc- Université Catholique de Louvain

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Drug resistant epilepsy is best managed by surgery. The goal of presurgical evalution is to correctly identify the epileptogenic zone, defined by the extent of cortical tissue that needs to be removed is order to achieve seizure freedom. When no causative lesion is identified, careful study of interictal activity is mandatory. Complementary analysis methods exist, designed to identify the source of electrical activity recorded with surface electro-encephalogram. While results are interesting in retrospective studies, the real clinical added value needs to be demonstrated with prospective studies. The company Epilog (Epilog, Ghent, Belgium) offers, with EPILOG PreOp®, a long-term EEG analysis to automatically detect epileptiform activity, combined with an estimation of the electrical source localization using a sLORETA inverse solution model. We will propose the EPILOG PreOp analysis to refractory epileptic patients with non-contributive cerebral imaging, under presurgical evaluation. By comparing the therapeutic decision with and without knowledge of the results of EPILOG PreOp®, we will establish the added clinical value of EPILOG PreOp®.
Detailed Description
Saint-Luc University Hospital (CUSL) are the sponsor of the study. The study is bi-centric, in collaboration with the William Lennox Neurological Hospital Center (CHNWL). Will be included prospectively the first thirty patients with refractory focal epilepsy being evaluated at CUSL or CHNWL between for surgery, and for whom the cerebral MRI 3 Tesla (3T) did not show any obvious causal lesion. The pre-surgical evaluation includes (standard of care - SOC): EEG-video scalp monitoring (SOC) MRI 3Tesla (SOC) PET scan FDG (SOC) neuropsychological assessment (SOC) MRI examination will be reviewed by an experienced neuroradiologist at CUSL (SOC). The automated EEG analysis and electrical source localization with EPILOG PreOp® (non-SOC) will be carried out by Epilog (Epilog, Ghent, Belgium), blind to the rest of the workup. The costs of this analysis are 250 € / patient and will be covered by a clinical research fund. If the patient is referred by the CUSL, the costs are charged to account 830 E. If the patient is referred by the CHNWL, the costs are charged to a local scientific account. The results of the pre-surgical evaluation will be discussed in a multidisciplinary meeting, blind to the results of EPILOG PreOp®, in order to determine the presumed localization of the epileptogenic zone as well as the management plan. The result of this discussion will be classified as follows: A focal surgical resection is possible; B the assessment must be completed by an invasive EEG (SOC); C the option of resective surgery is rejected. If an invasive EEG is considered, the anatomical location of electrodes is planned. Then, the results of EPILOG PreOp® are presented (by Dr. Susana Ferrao Santos) and their influence on the management is evaluated. The possible change of care in relation to the initial plan is considered to be relevant if the EPILOG PreOp® analysis results in a modification of the therapeutic decision as defined above, a modification of the invasive EEG implantation plan or the use of an additional non-invasive imaging method to delineate the epileptogenic zone or to establish the functional risk. Patients will then be followed for 6 months to determine the clinical relevance of any management changes derived from the EPILOG PreOp® analysis. We will also evaluate the relationship between the localization of the EPILOG + regions (ie the brain regions involved in the irritative zone according to the results provided by the EPILOG PreOp® analysis), the surgical resection, the pathology analysis results and post-surgical results. EPILOG PreOp® analysis will be carried out using the full length EEG recording collected during video-EEG monitoring (SOC) at CUSL or CHNWL, ie 7 days of recording. with 19-27 electrodes placed according to the international 10-20 system. The EEG data will be transmitted after acquisition and anonymization. For patients investigated at CHNWL, a high-density (non-SOC) recording with 64-76 electrodes will be offered for 24 to 48 hours if the investigator deems it necessary. The additional costs associated with high density EEG are borne by the CHNWL. The result will also be sent to Epilog for analysis, after anonymisation of the data. The EPILOG PreOp® analysis will begin with automated detection of interictal epileptiform activity using the Persyst program (Persyst Spike Detector P13, Persyst, San Diego, CA, USA), and interictal activity will be clustered and localized. source will be estimated using the sLORETA inverse solution model, using the methodology described previously. Pathology For all patients undergoing resective surgery, histological sections will be reviewed (SOC). Focal cortical dysplasias will be classified according to the ILAE (SOC) classification. Non-contributory results include: gliosis, absence of microscopic or histological abnormality.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Epilepsies, Partial
Keywords
epilepsy, drug resistant epilepsy, electrical source imaging, surgery

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
All patients included will have Epilog Preop analysis
Masking
None (Open Label)
Masking Description
Investigator has no access to Epilog Preop result during first case description.
Allocation
N/A
Enrollment
30 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Epilog Preop
Arm Type
Experimental
Arm Description
patients receive Epilog preop analysis
Intervention Type
Diagnostic Test
Intervention Name(s)
electrical source imaging
Intervention Description
automated analysis of surface EEG with electrocal source imaging
Primary Outcome Measure Information:
Title
Quantification of Epilog+ driven changes of management plan
Description
Descriptive analysis of population with results from Epilog Preop analysis that changed initial clinical decision (total number of patients, type management plan modification)
Time Frame
up to 6 months after recruitment
Secondary Outcome Measure Information:
Title
Sensitivity and specificity of Epilog+ compared to resection zone
Description
Are Epilog+ results in the same location as the resection zone?
Time Frame
up to 24 months after recruitment
Title
Sensitivity and specificity of Epilog+ compared to pathology
Description
Are Epilog+ results identifying abnormal cortex?
Time Frame
up to 24 months after recruitment
Title
Sensitivity and specificity of Epilog+ compared to seizure outcome
Description
What proportion of patients are seizure free if Epilog+ results are resected; what proportion of patients are not seizure free if Epilog + results are not resected?
Time Frame
up to 24 months after recruitment
Other Pre-specified Outcome Measures:
Title
added value of high density EEG + Epilog PreOp
Description
Are results obtained with Epilog Preop from high density EEG better?
Time Frame
up to 24 months after recruitment

10. Eligibility

Sex
All
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: drug resistant epilepsy under presurgical evaluation non lesional 3Tesla MRI scan epileptic seizure(s) recorded during video-EEG monitoring Exclusion Criteria: patient does not agree for follow-up during 6 months patient has an obvious causal lesion on MRI scan
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Susana Ferrao Santos, MD, PhD
Phone
027647801
Email
susana.ferrao@uclouvain.be
Facility Information:
Facility Name
Saint-Luc University Hospital
City
Brussels
ZIP/Postal Code
1200
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Susana Ferrao Santos, MD, PhD
Phone
003227647801
Email
susana.ferrao@uclouvain.be
Facility Name
Centre Hospitalier William Lennox
City
Ottignies
ZIP/Postal Code
1340
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pascal Vrielynck, MD
Phone
003210430338
Email
pascal.vrielynck@chnwl.be

12. IPD Sharing Statement

Learn more about this trial

Added Value of Automated Electrical Source Localization (EPILOG PreOp®) to Presurgical Evaluation of Refractory Epilepsy

We'll reach out to this number within 24 hrs